Brokerages Set Cardlytics, Inc. (NASDAQ:CDLX) Target Price at $6.92

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have been given an average recommendation of “Reduce” by the seven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $6.92.

A number of brokerages recently issued reports on CDLX. Northland Capmk downgraded Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Evercore ISI assumed coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target for the company. Bank of America lowered shares of Cardlytics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $4.00 to $3.50 in a report on Thursday, August 15th. Needham & Company LLC downgraded shares of Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, Craig Hallum lowered Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th.

Cardlytics Stock Performance

NASDAQ:CDLX opened at $3.78 on Tuesday. The company’s 50-day moving average is $3.61 and its two-hundred day moving average is $7.37. Cardlytics has a 1-year low of $2.89 and a 1-year high of $20.52. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.77 and a quick ratio of 1.77. The firm has a market capitalization of $184.40 million, a price-to-earnings ratio of -0.86 and a beta of 1.67.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. The firm had revenue of $69.64 million for the quarter, compared to analysts’ expectations of $75.39 million. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The firm’s quarterly revenue was down 9.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.57) earnings per share. Analysts forecast that Cardlytics will post -1.72 EPS for the current year.

Insider Buying and Selling

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Scott A. Hill acquired 40,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, with a total value of $143,200.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $143,200. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of the stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,573 shares of company stock valued at $151,612 in the last three months. 4.40% of the stock is owned by corporate insiders.

Institutional Trading of Cardlytics

A number of institutional investors have recently bought and sold shares of CDLX. Quadrature Capital Ltd acquired a new stake in shares of Cardlytics during the 1st quarter worth about $1,906,000. Vanguard Group Inc. raised its holdings in Cardlytics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after purchasing an additional 57,805 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Cardlytics by 711.9% during the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares in the last quarter. Susquehanna Fundamental Investments LLC lifted its position in shares of Cardlytics by 13.8% during the 1st quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock worth $457,000 after buying an additional 3,836 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Cardlytics by 15.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock valued at $1,116,000 after buying an additional 18,179 shares in the last quarter. 68.10% of the stock is owned by hedge funds and other institutional investors.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.